Cereno Scientific announces licensing agreement for the drug candidate CS585 with University of Michigan (UoM)
Cereno Scientific (XSAT: CRNO B) today announced that the company has signed a license agreement for the drug candidate CS585 with the University of Michigan. The signed agreement provides Cereno the exclusive rights to CS585 for further clinical development and commercialization. Cereno also extends the preclinical collaboration agreements it has with UoM for the two programs CS585 and CS014.“We are pleased to enter this licensing agreement with the University of Michigan. It is a great fit with our growth strategy and provides value to our portfolio within pulmonary arterial hypertension (